Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox's lead program in clinical development is bimatoprost grenod (NCX 470), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox SA generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the United States, and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets.

Employees

Sector

Pharmaceuticals

More about the company

Market Cap	32.61M 37.83M 30.01M 28.15M 52.88M 3.58B 53.41M 355M 139M 1.75B 142M 139M 6.06B	P/E Ratio 2026 *	34.7x	P/E Ratio 2027 *	2.89x
Enterprise Value	32.61M 37.83M 30.01M 28.15M 52.88M 3.58B 53.41M 355M 139M 1.75B 142M 139M 6.06B	EV / Sales 2026 *	3.26x	EV / Sales 2027 *	1.63x
Free-Float	99.65%	Yield 2026 *	-	Yield 2027 *	-

04-29	Nicox S.A. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
02-24	Nicox SA Highlights Positive NCX 470 Phase 3 Data Confirming Therapeutic Profile at the 2026 American Glaucoma Society Annual Meeting	CI
02-24	Edenred, Forvia, Freelance.com... Key Stocks to Watch Today in Paris -
02-24	Nicox Reports Positive Phase 3 Results for NCX 470
02-16	Nicox, Sanofi, Valneva... Stocks to Watch Today in Paris
02-16	Nicox Moves Forward with U.S. Health Authorities for Its NCX 470
01-05	Nicox Strengthens Its Financial Position
01-05	Exail, Alstom, Equasens... Stocks to Watch Today in Paris
01-05	Nicox Repays Debts to Kreos Capital, Extends Cash Runway	MT
01-05	Nicox: To Watch Today
01-05	Nicox Repays Debt with Kreos Capital and Extends Its Financing Horizon
01-04	Nicox S.A. announced that it expects to receive ?4.000031 million in funding	CI
12-16	Nicox SA Completes NCX 470 New Drug Application Key Data Generation for Submission as Planned in First First 2026	CI

06-08	Reminder: Nicox June 2024 Warrants will expire June 19, 2026	GL
06-03	Nicox: Notice of the Ordinary and Extraordinary Shareholders’ Meeting on June 24, 2026 and appointment of an ad hoc representative	GL
04-30	Nicox Provides Full Year 2025 Financial Results and Corporate Update	GL
04-20	Reminder: Last Exercise Day for Nicox June 2024 Warrants is June 19, 2026	GL
02-24	Nicox Highlights Positive NCX 470 Phase 3 Data Confirming Therapeutic Profile at the 2026 American Glaucoma Society Annual Meeting	GL

06-08	Rappel : les BSA Nicox de juin 2024 expireront le 19 juin 2026
06-03	Nicox : Report from the Board of Directors on the resolutions submitted to the approval of the shareholders meeting 2026 (in French)
06-03	Nicox : Convocation à l’Assemblée Générale Ordinaire et Extraordinaire le 24 juin 2026 et désignation d’un mandataire ad hoc
04-30	Nicox annonce ses résultats financiers 2025 et fait un point sur son activité
04-20	Rappel : le dernier jour d’exercice pour les Bons de Souscription d’Actions (BSA) Nicox de juin 2024 est le 19 juin 2026

Manager	Title	Age	Since
Gavin Spencer CEO	Chief Executive Officer	55	2024-02-27
Sandrine Gestin DFI	Director of Finance/CFO	58	2014-12-31
Doug Hubatsch CTO	Chief Tech/Sci/R&D Officer	-	2021-12-12

NicOx SA Stock Euronext Paris

Stocks

NCOX

FR0000074130

Pharmaceuticals

Valuation: NicOx SA

Latest news : NicOx SA

Press Releases: NicOx SA

News in other languages: NicOx SA

Quotes and Performance

Managers and Directors: NicOx SA

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Director	Title	Age	Since
Gavin Spencer BRD	Director/Board Member	55	2024-04-07
Damian Marron CHM	Chairman	64	2024-07-15
Marc Bozec BRD	Director/Board Member	-	2024-07-15

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NICOX SA	-7.95%	-9.39%	-	-	35.36M
MERCK & CO., INC.	-2.79%	-3.87%	+41.92%	+5.03%	294B
MERCK KGAA	-0.41%	-3.03%	+15.59%	-21.08%	67.08B
KYOWA KIRIN CO., LTD.	-0.50%	+4.35%	-4.06%	-12.73%	7.84B
SK BIOPHARMACEUTICALS CO., LTD.	+2.62%	+2.38%	-0.11%	+12.61%	4.54B
YUHAN CORPORATION	+2.20%	+1.81%	-25.92%	+39.70%	3.8B
BETTA PHARMACEUTICALS CO., LTD.	-0.95%	+9.14%	-15.76%	+8.37%	3.35B
SUPERNUS PHARMACEUTICALS, INC.	-1.24%	-1.39%	+35.08%	+30.57%	2.58B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+0.94%	+2.25%	+6.66%	-21.06%	1.98B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	-1.72%	-4.46%	-20.96%	-24.65%	1.73B
Average	-0.96%	+1.16%	+3.61%	+1.86%	42.99B
Weighted average by Cap.	-1.93%	-1.39%	+34.26%	+0.50%

	2026 *	2027 *
Net sales	10M 11.6M 9.2M 8.63M 16.22M 1.1B 16.38M 109M 42.5M 537M 43.54M 42.62M 1.86B	20M 23.2M 18.41M 17.27M 32.44M 2.19B 32.76M 218M 85M 1.07B 87.08M 85.23M 3.72B
Net income	1M 1.16M 920K 863K 1.62M 110M 1.64M 10.88M 4.25M 53.7M 4.35M 4.26M 186M	11M 12.76M 10.12M 9.5M 17.84M 1.21B 18.02M 120M 46.75M 591M 47.89M 46.88M 2.04B
Net Debt	-	-